Baker Bros. Advisors LP Mereo Biopharma Group PLC Transaction History

Baker Bros. Advisors LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.79 - $1.43 $2.81 Million - $5.08 Million	3,554,979 New	3,554,979 $4.69 Million
Q4 2021 Feb 14, 2022	SELL	$1.51 - $2.59 $441,964 - $758,072	-292,692 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$2.2 - $3.17 $4.77 Million - $6.87 Million	-2,166,707 Reduced 88.1%	292,692 $708,000
Q2 2021 Aug 16, 2021	SELL	$2.94 - $4.08 $12.5 Million - $17.4 Million	-4,260,549 Reduced 63.4%	2,459,399 $7.8 Million
Q1 2021 May 17, 2021	BUY	$2.6 - $4.43 $1.79 Million - $3.06 Million	689,655 Added 11.44%	6,719,948 $22.6 Million
Q4 2020 Feb 16, 2021	BUY	$1.95 - $3.6 $11.8 Million - $21.7 Million	6,030,293 New	6,030,293 $21.6 Million

107M

209K

479K

Ticker MREO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,986,000
Market Cap $437M
Description
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Baker Bros. Advisors LP with notifications on news.